Correlation Between Walker Dunlop and Ironwood Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Walker Dunlop and Ironwood Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Walker Dunlop and Ironwood Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Walker Dunlop and Ironwood Pharmaceuticals, you can compare the effects of market volatilities on Walker Dunlop and Ironwood Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Walker Dunlop with a short position of Ironwood Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Walker Dunlop and Ironwood Pharmaceuticals.

Diversification Opportunities for Walker Dunlop and Ironwood Pharmaceuticals

-0.16
  Correlation Coefficient

Good diversification

The 3 months correlation between Walker and Ironwood is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Walker Dunlop and Ironwood Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ironwood Pharmaceuticals and Walker Dunlop is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Walker Dunlop are associated (or correlated) with Ironwood Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ironwood Pharmaceuticals has no effect on the direction of Walker Dunlop i.e., Walker Dunlop and Ironwood Pharmaceuticals go up and down completely randomly.

Pair Corralation between Walker Dunlop and Ironwood Pharmaceuticals

Allowing for the 90-day total investment horizon Walker Dunlop is expected to generate 0.32 times more return on investment than Ironwood Pharmaceuticals. However, Walker Dunlop is 3.17 times less risky than Ironwood Pharmaceuticals. It trades about 0.01 of its potential returns per unit of risk. Ironwood Pharmaceuticals is currently generating about -0.22 per unit of risk. If you would invest  9,373  in Walker Dunlop on February 28, 2024 and sell it today you would lose (43.00) from holding Walker Dunlop or give up 0.46% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Walker Dunlop  vs.  Ironwood Pharmaceuticals

 Performance 
       Timeline  
Walker Dunlop 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Weak
Over the last 90 days Walker Dunlop has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound fundamental indicators, Walker Dunlop is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders.
Ironwood Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Ironwood Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in June 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Walker Dunlop and Ironwood Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Walker Dunlop and Ironwood Pharmaceuticals

The main advantage of trading using opposite Walker Dunlop and Ironwood Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Walker Dunlop position performs unexpectedly, Ironwood Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ironwood Pharmaceuticals will offset losses from the drop in Ironwood Pharmaceuticals' long position.
The idea behind Walker Dunlop and Ironwood Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Complementary Tools

Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance